Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior

International Journal of Radiation Oncology Biology Physics

Volumn 34, Issue 3, 1996, Pages 549-553

  Hanks, Gerald E ^a   Hanlon, Alexandra L ^a   Lee, W Robert ^a   Slivjak, Anne ^a   Schultheiss, Timothy E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Prostate cancer; PSA doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

EID: 0030047278     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02154-X     Document Type: Article

References (15)

1. Carter, H. B.; Pearson, J. D.; Metter, E. J.; Brant, L. J.; Chan, D. W.; Andres, R.; Fozard, J. L.; Walsh, P. C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220; 1992.
2. Crook, J.; Robertson, S.; Esche, B. Proliferative cell nuclear antigen in postradiotherapy prostate biopsies. Int. J. Radiat. Oncol. Biol. Phys. 30:303-308; 1994.
3. D'Amico, A.; Hanks, G. E. Linear regressive analysis using PSA doubling time predicts tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643; 1993.
4. Hanks, G. E.; D'Amico, A.; Epstein, B.; Schultheiss, T. Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int. J. Radiat. Oncol. Biol. Phys. 27:125-127; 1993.
5. Hanks, G. E.; Lee, W. R.; Schultheiss, T. E. Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J. Urol. 154:456-459; 1995.
6. Kalbfleisch, J. D.; Ross, L. P. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
7. Kaplan, E. L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:447-457; 1958.
8. Lawless, J. E. Statistical models and methods for lifetime data. New York: John Wiley & Sons; 1982.
9. Lee, W. R.; Hanks, G. E.; Corn, B. W.; Schultheiss, T. E. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 31:21-24; 1995.
10. Partin, A. W.; Pearson, J. D.; Landis, P. K.; Carter, H. B.; Pound, C. R.; Clemens, J. A. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urol. 43:649-659; 1994.
11. Pollack, A.; Zagars, G. K.; El-Naggar, A.; Terry, N. H. A. Relationship of tumor DNA-ploidy to serum prostate specific antigen doubling time after radiotherapy for prostate cancer. Urology 44:711-718; 1994.
12. SAS Institute Inc. SAS technical report P-179, additional SAS/STAT procedures, release 6.03. Cary, NC: NCL SAS Institute Inc.; 1988:49-89.
13. Schmid, H. P.; McNeal, J. E.; Stamey, T. A. Observations on the doubling time of prostate cancer. Cancer 71:2031-2040; 1993.
14. Stamey, T. A.; Kabalin, J. N.; McNeal, J. E.; Johnstone, I. M.; Frieha, F.; Redwine, E. A.; Yang, N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol. 141:1076-1083; 1989.
15. Zagars, G. K.; Pollack, A. Radiation therapy for T1 and T2 prostate cancer: Postate-specific antigen and disease outcome. Urology 45:476-483; 1995.